PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL Therapy

DISEASE CHARACTERISTICS:

* Diagnosis of chronic myelogenous leukemia confirmed by bone marrow biopsy

  * Chronic, accelerated, or blastic phase disease
* May have T315I mutation in BCR-ABL kinase
* Relapsed after prior imatinib mesylate or c-ABL therapy
* No CNS leukemia

PATIENT CHARACTERISTICS:

* ECOG performance status 0-2
* Blood pressure ≤ 140/90 mm Hg (with or without hypertension treatment for ≥ 1 week)
* Transaminases ≤ 2.5 times upper limit of normal (ULN)
* Bilirubin ≤ 1.5 times ULN
* Creatinine ≤ 1.5 times ULN
* No known history of HIV infection
* No active uncontrolled infection
* No grade 3 or 4 bleeding
* LVEF ≥ 45% by MUGA or ≥ 40% by transthoracic echocardiography
* No medical or psychiatric condition or laboratory abnormalities that would limit study compliance or increase risk during study participation
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for 90 (female) or 180 (male) days after completion of study treatment
* No significant cardiovascular disease (i.e., uncontrolled arrhythmias or unstable angina) within the past 6 months
* No major thromboembolic event within the past 6 months, including any of the following:

  * Myocardial infarction
  * Stroke
  * Transient ischemic attack
  * Pulmonary embolism
  * Noncatheter-related deep-vein thrombosis

PRIOR CONCURRENT THERAPY:

* Recovered from all acute toxic effects (excluding alopecia) of prior therapy
* More than 2 weeks since prior chemoimmunotherapy

  * Hydroxyurea must be discontinued 1 day prior to study therapy
* More than 4 weeks since prior major surgery
* No other concurrent approved or investigational anticancer treatment, including chemotherapy, biologic response modifiers, hormones, or immunotherapy
* No other concurrent investigational drugs
* No concurrent participation in another treatment clinical trial